Abstract. Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), a coactivator interacting with multiple transcription factors, regulates several metabolic processes. Although recent studies have focused on the role of PGC-1α in cancer, the underlying molecular mechanism has not been clarified. Therefore, we evaluated the role of PGC-1α in cell proliferation and tumorigenesis using human embryonic kidney (HEK)293 cells and colorectal cancer cells. We established stable HEK293 cell lines expressing PGC-1α and examined cell proliferation, anchorage-independent growth, and oncogenic potential compared to parental HEK293 cells. To identify the molecular PGC-1α targets for increased cell proliferation and tumorigenesis, the GeneFishing™ DEG (differentially expressed genes) screening system was used. Western blot analysis and immunofluorescence staining were performed for a regulated gene product to confirm the results. Forced expression of PGC-1α in HEK293 cells promoted cell proliferation and anchorage-independent growth in soft agar. In addition, HEK293 cells that highly expressed PGC-1α showed enhanced tumor formation when subcutaneously injected into the bilateral flanks of immunodeficient mice. The results of the GeneFishing DEG screening system identified one upregulated gene (Acyl-CoA binding protein; ACBP). Real-time RT-PCR, western blot analysis, and immunofluorescence staining showed that ACBP was markedly increased in HEK293 cells stably overexpressing PGC-1α (PGC-1α-HEK293 cells) compared to those expressing an empty vector. In PGC-1α, ACBP, and specificity protein 1 (Sp1) siRNA knockdown experiments in PGC-1α-HEK293 and SNU-C4 cells, we also observed inhibition of cell proliferation, reduced expression of antioxidant enzymes, and increased H 2 O 2 -induced reactive oxygen species production and apoptosis. These findings suggest that PGC-1α may promote cell proliferation and tumorigenesis through upregulation of ACBP. We provide evidence that increased Sp1 expression might contribute to enhanced ACBP expression by PGC-1α. The current results also suggest that PGC-1α, whose expression is related to enhanced cell proliferation and tumorigenesis, may be a good candidate molecular target for cancer therapy.
Introduction
Many biological responses are regulated at the transcriptional level by interaction of transcription factors with transcriptional coactivators. For example, the peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α) is a strong coactivator for PPARγ, which is expressed in human heart, kidney, liver, and skeletal muscle, with only very low levels in white adipose tissue and small and large intestine (1) . The PGC-1 family is integral to the coordinated activation of transcription complexes (2, 3) that regulate global responses such as mitochondrial biogenesis (1, 4) and tissue-specific responses such as adaptive thermogenesis (1), fatty acid oxidation (5, 6) , hepatic gluconeogenesis (7, 8) , fiber type switching in skeletal muscle (9) , reactive oxygen species (ROS) metabolism (10) , and clock gene expression (11) . It also interacts with a number of other nuclear receptors such as glucocorticoid receptor (12) , nuclear respiratory factor-1 (4), hepatocyte nuclear factor 4α (13) , estrogen receptor α (8) , PPARα (5), retinoid X receptor (14) , and estrogen-related receptor α (15) . PGC-1α contains a powerful autonomous transactivation domain at its N-terminus (aa ) that binds two other coactivators with acetyltransferase activity, steroid receptor coactivator-1 (SRC-1) and CBP/p300 (11) . PGC-1α lacks acetyltransferase activity, thus requiring interaction with coactivators such as SRC-1 for regulation of target genes.
Recent studies have focused on the role of several coactivators in cancer. In particular, a role of PGC-1α in cancer has been controversial. Some studies have shown that the expres-
Overexpression of PGC-1α enhances cell proliferation and tumorigenesis of HEK293 cells through the upregulation of Sp1 and Acyl-CoA binding protein
sion level of PGC-1α decreases in certain cancer tissues such as breast (16, 17) and colon cancers (18) , but another study demonstrated that PGC-1α overexpression induces apoptosis in ovarian cancer cells (19) . In contrast, PGC-1α is a suppressor of ROS (10) , protecting cells from apoptosis in neuroblastoma cells (20) and promoting cell growth in prostate cancer cells (21) , which suggests that PGC-1α may be involved in cancer pathogenesis. Thus, to date, the effect of PGC-1α in cell proliferation and tumorigenesis has not been completely clarified.
In this study, therefore, the role of PGC-1α in cell proliferation and tumorigenesis and the possible molecular mechanisms for its effect were evaluated using a stable human embryonic kidney (HEK)293 cell line expressing PGC-1α and the GeneFishing DEG (differentially expressed genes) screening system (Seegene, Seoul, Korea).
Materials and methods
Cell preparations. The HEK293, human colon cancer HT-29 and SNU-C4, and mouse colon cancer CT-26 cells were obtained from the Korean Cell Line Bank (Seoul National University, Seoul, Korea) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin (Gibco, Carlsbad, CA, USA). Cultures were maintained in a humidified atmosphere of 95% air/5% CO 2 at 37˚C.
Materials. 2', 7'-dichlorofluorescein diacetate (DCFDA)
and carboxyfluorescein succinimidyl ester (CFSE) were obtained from Molecular Probes (Carlsbad, CA, USA). The Annexin V-FITC apoptosis detection kit was obtained from BD Biosciences (San Jose, CA, USA). Anti-PGC-1α (sc-13067), anti-ACBP (sc-30190), anti-superoxide dismutase (SOD)-2 (sc-30080), anti-specificity protein 1 (Sp1) (sc-59), anti-rabbit IgG-FITC (sc-2012), anti-rabbit IgG-PE (sc-3739), and anti-mouse IgG-FITC (sc-2010) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-catalase antibody (ab1877) was purchased from Abcam (Cambridge, UK). The anti-FLAG ® (F7425), anti-β-actin (A1978), anti-rabbit IgG (A0545), and anti-mouse IgG secondary antibodies (A9044) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Unless stated otherwise, all other chemicals were purchased from Sigma.
Transfection and establishment of stable cell lines expressing the PGC-1α vector. HEK293 and CT-26 cells (1x10 6 ) were transfected with 4 µg of pcDNA3.1-FLAG-PGC-1α expression vector from Spiegelman or empty vector (pcDNA 3.1) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommended procedure. After transfection, stable cell lines were established after G418 selection (800 µg/ml) for 14 days. Stable cell lines were cultured in DMEM supplemented with 10% FBS, 800 µg/ml G418, 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco). Cultures were maintained in a humidified atmosphere of 95% air/5% CO 2 at 37˚C.
Real-time RT-PCR analysis.
Total RNA was extracted using RNAeasy mini kits (Qiagen, Valencia, CA, USA). Reverse transcription was performed using the RevertAid First Strand cDNA synthesis kit with a random hexamer as the primer (Thermo Scientific, Chicago, IL, USA). Real-time reverse transcriptase PCR (RT-PCR) was carried out on total RNA from HEK293 and HEK293-PGC-1α #1 cells transfected with PGC-1α and ACBP-specific or non-specific control small-interfering (si) RNA after 48 h on an ABI PRISM 7500 Sequence Detection System instrument (Applied Biosystems, Foster City, CA, USA). Each real-time RT-PCR was done in triplicate according to the manufacturer's instructions. TaqMan™ Gene expression assays [diazepam binding inhibitor (DBI)/ACBP (Hs01554584_m1)] were from Applied Biosystems. Quantification was based on a comparative ∆Ct method using glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Hs03929097_g1) as endogenous control.
Western blot analysis. Cells were harvested, washed with phosphate-buffered saline (PBS), and treated with lysis buffer containing 20 mmol/l Tris (pH 8.0), 137 mmol/l NaCl, 10% glycerol, 1% Nonidet P-40, 10 mmol/l EDTA, 100 mmol/l NaF, 1 mmol/l phenylmethylsulfonyl fluoride and 10 mg/ml leupeptin. The lysates were centrifuged at 13,000 rpm for 15 min and the concentration of protein in each lysate determined using Bio-Rad protein assay reagent (Bio-Rad, Richmond, CA, USA) following the manufacturer's suggested procedure. Then, 8, 10 or 12% SDS-PAGE was used to separate 30 µg protein samples. Following electrophoresis, proteins were transferred to nitrocellulose membranes (Amersham Life Science, Inc., Arlington Heights, IL, USA). Blots were blocked overnight in 5% skim milk in PBS at 4˚C and subsequently probed with primary antibody overnight. The blots were also probed with a monoclonal anti-β-actin antibody (Sigma) to be quantified as a relative loading control. Detection of specific proteins was carried out with enhanced chemiluminescence detection reagents (Amersham Life Science, Inc.) following the manufacturer's instructions. Bands were quantified using Image Studio Lite Ver 3.1. (LI-COR, Inc., Lincoln, NE, USA) Cell counting. HEK293, PGC-1α-HEK293, CT-26, and PGC-1α-CT-26 cells were seeded at a density of 1x10 5 /well in a 6-well plate. PGC-1α-HEK293 and SNU-C4 cells transfected with siRNAs for PGC-1α, ACBP, Sp1, or non-specific control siRNA were seeded at a density of 1x10 5 /well in a 6-well plate. After a 24-, 48-or 72-h culture, the cells were harvested by trypsinization using trypsin/EDTA and stained with trypan blue. The vital cells (those not stained with trypan blue) were counted under the microscope (Nikon Eclipse TS100; Nikon, Tokyo, Japan). Three independent experiments were carried out.
Cell proliferation assay. Cell proliferation was measured using the CFSE labeling assay as previously described (22) . CFSE, which is used to fluorescently label live cells, is equally partitioned to daughter cells during division and can be used to measure cell proliferation. Briefly, cells were washed three times with PBS and incubated with 1 µM CFSE dye (Molecular Probes) for 15 min. The cells were then washed again, incubated with fresh medium containing 10% FBS, and seeded in 6-well plates at a density of 1x10 5 
Annealing control primer (ACP)-based GeneFishing PCR.
Differentially expressed genes were screened using the ACP-based PCR method (23) with the GeneFishing DEG kits (Seegene). Briefly, second-strand cDNA synthesis was conducted at 50˚C during one cycle of first-stage PCR in a final reaction volume of 20 µl containing 3-5 µl (~50 ng) of diluted first-strand cDNA, 1 µl of dT-ACP2 (10 µM), 1 µl of 10 µM arbitrary ACP and 10 µl of 2X Master Mix (Seegene). The PCR protocol for second-strand synthesis was one cycle at 94˚C for 1 min, followed by 50˚C for 3 min and 72˚C for 1 min. After second-strand DNA synthesis was completed, the second-stage PCR amplification protocol was 40 cycles of 94˚C for 40 sec, followed by 65˚C for 40 sec and 72˚C for 40 sec and a 5-min final extension at 72˚C. The amplified PCR products were separated on a 2% agarose gel stained with ethidium bromide. The amplified cDNA fragments with >2-fold differential band intensities were re-amplified and extracted from the gel by using the GeneClean II kit (Qbiogene, Solon, OH, USA), and directly sequenced with an ABI PRISM 310 Genetic Analyzer (Applied Biosystems).
Annexin V-PI staining assay. The extent of apoptosis was evaluated by Annexin V-FITC and flow cytometry as previously described (24) . The Annexin V assay was used, in which Annexin was conjugated with FITC. Propidium iodide (PI) was used as counterstain. Briefly, cells were treated with 0.5, 1 or 2 mM H 2 O 2 for 24 h. After incubation, cells were harvested, washed with PBS (pH 7.4), centrifuged, and stained with Annexin V-FITC (BD Pharmingen, San Diego, CA, USA) and 2 µg/ml PI in binding buffer (10 mM HEPES, pH 7.4/140 mM NaCl/2.5 mM CaCl 2 ) for 15 min at 37˚C in the dark. The samples were analyzed by flow cytometry using a FACScan flow cytometer. Data analysis was performed using CellQuest software (Becton-Dickinson, San Jose, CA, USA).
Soft-agar colony formation assay (25) . HEK293 cells (2.0x10 4 ) overexpressing PGC-1α or empty vector were suspended in 1 ml of 0.3% agarose (Sigma) and then added to 1-of a 6-well plate with a foundation layer of 0.5% agarose in triplicate. Approximately 24 h later, the cells received an additional 1 ml of growth medium before incubation for a further 14 days. Colonies were stained with 0.01% crystal violet and counted under the microscope (Nikon) in 20 fields of x10 magnification. Light microscopy images were captured under x100 magnification.
Effect of PGC-1α on the tumor formation. All animal procedures and care were approved by the Institutional Animal Care and Usage Committee of Dong-A University. To determine the effect of PGC-1α on tumor formation, viable HEK293 cells (2x10 7 cells/100 µl) overexpressing PGC-1α or empty vector were subcutaneously injected into the bilateral flanks of 6-to 7-week-old female nu/nu immunodeficient BALB/c mice, respectively (Orient Bio Inc., Seongnam, Korea). Tumor size was measured daily with a caliper (calculated volume = shortest diameter 2 x longest diameter/2). The mice were followed for tumor size and sacrificed on the 45th day. Tumors were resected, weighed, and frozen or fixed in formalin and paraffin-embedded for immunofluorescence staining.
Immunofluorescence staining. Cells were cultured on a Lab-Tek ® Chamber Slide™ (Nalgen Nunc Inc., Rochester, NY, USA) and then fixed with 3% formaldehyde and permeabilized using 0.01% Triton X-100. After being blocked with 3% FBS for 30 min, cells were incubated in primary antibody for 1 h followed by a fluorescence-labeled secondary antibody (Sigma) for 30 min. Cells were then washed, mounted using glycerol, and analyzed by confocal microscope (Zeiss LSM 510 confocal microscope; Carl Zeiss Co., Ltd., Jena, Germany) using a 40x C-Apochromat objective. Negative control staining was performed with secondary antibodies alone.
Assessment of ROS production. ROS production was monitored by flow cytometry using carboxy-H 2 DCFDA (Molecular Probes). PGC-1α-HEK293 and SNU-C4 cells transfected with siRNAs for PGC-1α, ACBP, or Sp1, or with non-specific control siRNA were washed twice with PBS to remove the extracellular compounds. H 2 DCFDA (100 µmol/l) was added for an additional hour. Green fluorescence was excited using an argon laser and detected using a 525-nm band-pass filter by flow cytometric analysis.
siRNA transfection. The siRNA sequence used for the targeted silencing of PGC-1α, ACBP, or Sp1 was designed by Qiagen (GS10891), Dhamacon (L-006488-00-0005, Thermo Scientific, Chicago, IL, USA), or Santa Cruz (sc-29487), respectively. For transfection, cells were resuspended at 1.3x10 7 /0.5 ml in PBS and mixed with 4 nM siRNA for PGC-1α, 4 nM siRNA for ACBP, or 4 nM siRNA for Sp1, or with 4 nM non-silencing siRNA using Lipofectamine 2000 (Invitrogen) following the manufacturer's procedure. After transfection, cells were cultured in 10% FBS-supplemented DMEM for 48 h. These cells were then used for cell proliferation, Annexin V-PI staining, assessment of ROS production, immunofluorescence staining, real-time RT-PCR and western blot analysis.
Immunoprecipitation. PGC-1α-HEK293 #1 cells were washed in PBS and centrifuged at 1,000 rpm for 5 min to harvest the cells. Ice-cold modified RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 µg/ml each of aprotinin, leupeptin, and pepstatin, 1 mM Na 3 VO 4 , 1 mM NaF) was added to the cells, which were gently rocked on a rocker at 4˚C for 15 min for cell lysis. The lysate was centrifuged at 14,000 rpm for 15 min at 4˚C and pre-cleared by addition of 100 µl of 50% Protein G sepharose bead slurry per 1 ml of cell lysate. The supernatant was incubated with specific antibody overnight at 4˚C with gentle rocking. The immune complex was captured by the addition of 100 µl Protein G sepharose (Invitrogen). The sepharose beads were washed three times with 800 µl ice-cold RIPA buffer and resuspended in 60 µl 2X sample buffer, followed by elution through boiling. The immune complexes were fractionated on 10% SDS-PAGE followed by western blotting with appropriate antibodies.
Statistical analyses. Statistical analyses were done with the SPSS 21.0 statistical package for Windows (SPSS, Chicago, IL, USA). Data are expressed as mean values ± standard deviation (SD). One-way ANOVA was used to determine whether there were significant differences in cell viability between PGC-1α-HEK293 #1 cells, PGC-1α-HEK293 #3 cells and HEK293 wild-type cells. Differences in tumor volumes between control HEK293 cell-injected and PGC-1α-HEK293 cell-injected groups were evaluated using the unpaired Student's t-test. Statistical significance was defined as P<0.05.
Results

PGC-1α accelerates proliferation of HEK293 and CT-26 cells.
As a first step toward assessing the functional significance of PGC-1α overexpression for growth of cells, HEK293 and CT-26 cells were transiently transfected with a FLAGtagged PGC-1α expression vector or with the parental vector (pcDNA 3.1) and cultured with G418 (800 µg/ml) for 14 days. After that, several colonies were picked and amplified. Exogenously expressed PGC-1α was detected by western blotting and immunofluorescence staining with antibodies against PGC-1α and FLAG. As shown in Fig. 1A , the protein of PGC-1α in PGC-1α-HEK293 #1, PGC-1α-HEK293 #3, and PGC-1α-CT-26 #9 cells was increased compared to wild-type or pcDNA-transfected HEK293 and CT-26 cells. In addition, the exogenously expressed FLAG-tagged PGC-1α (FLAG-PGC-1α) was detected in PGC-1α-transfected HEK293 (PGC-1α-HEK293 #1 and #3) and PGC-1α-transfected CT-26 (PGC-1α-CT-26 #9) cells (Fig. 1B) .
To investigate the effect of PGC-1α overexpression on growth of HEK293 and CT-26 cells, cell viability and proliferation were determined by cell counting and CFSE labeling assays. As shown in Fig. 1C , the average number of cells in PGC-1α-transfected HEK293 and CT-26 cells (PGC-1α-HEK293 #1 and #3; 16.1x10 5 and 15.5x10 5 at 72 h, respectively; PGC-1α-CT-26 #9; 11.9x10 5 at 72 h) was significantly higher than in wild-type HEK293 and CT-26 cells (3.9x10 5 at 72 h; 7.9x10 5 at 72 h, respectively). In addition, as expected, the number of cells with high fluorescence decreased with days in culture, so that the peak signals for PGC-1α-transfected cells (PGC-1α-HEK293 #1, #3 and PGC-1α-CT-26 cells) were shifted to the left compared to control cells (Fig. 1D) . Thus, CFSE labeling analysis confirmed that PGC-1α overexpression enhances cell proliferation of HEK293 and CT-26 cells.
Knockdown of PGC-1α expression results in decreased cell proliferation of human colorectal cancer cells.
The effect of PGC-1α on cell proliferation was further investigated using siRNA transfection to knock down endogenous PGC-1α expression in human colorectal cancer HT-29 and SNU-C4 cells. At 72 h after transfection, PGC-1α expression was 40 and 53% lower than in wild-type or non-specific control siRNA-transfected HT-29 and SNU-C4 cells, respectively ( Fig. 2A and B) . Concurrently, proliferation of PGC-1α siRNA-transfected HT-29 and SNU-C4 cells at 48 h posttransfection was significantly suppressed in comparison with that of untreated or non-silencing siRNA-transfected cells (37.2 and 33.5% reduction, respectively; P<0.01) by cell counting and CFSE labeling (Fig. 2C) . In addition, PGC-1α siRNA transfection repressed cell proliferation by 26% at 48 h post-transfection in PGC-1α-HEK293 #1 cells (Fig. 2C) . Taken together, these results support an important role of PGC-1α in the regulation of cell proliferation.
PGC-1α promotes the oncogenic potential of HEK293 cells.
Because anchorage-independent growth is considered to be an in vitro test for tumorigenesis, we assayed the effects of overexpression of PGC-1α on the ability of HEK293 cells to form colonies in soft agar. As shown in Fig. 3A , overexpression of PGC-1α in HEK293 cells resulted in a higher incidence of colony formation than observed following transfection with the empty vector (114. 4±13.6 and 67.8±6.6, P<0.001, respectively). The cells transfected with empty vector formed no colonies during 14 days of culture whereas both cell lines expressing PGC-1α formed a significantly high number of colonies of a large size (Fig. 3A) . In addition, to confirm the impact of PGC-1α overexpression on tumorigenesis, wild-type HEK293 cells or PGC-1α-overexpressing HEK293 cells were injected subcutaneously into bilateral flanks of immunodeficient Balb/c mice, and tumor development and size were examined. Wild-type HEK293 cells formed tumors at a low percentage (6.67±6.67%) whereas the matched PGC-1α-HEK293 cells (PGC-1α-HEK293 #1 and PGC-1α-HEK293 #3) formed tumors in 76.67±8.82 and 60.00±15.30% of mice, respectively ( Fig. 3B and C) . In addition, the average tumor size in mice with PGC-1α-HEK293 #1 (652.1±263.5 mm 3 ) was larger than in mice with PGC-1α-HEK293 #3 (217.3±75.9 mm 3 ), suggesting that the expression level of PGC-1α is related to tumor growth. Furthermore, the presence of tumor cells was confirmed by hematoxylin and eosin staining (Fig. 3D) . Thus, these data suggest that PGC-1α overexpression dramatically enhances the tumorigenic capacity of HEK293 cells in Balb/c nude mice.
Decreased sensitivity to oxidative stress in PGC-1α-overexpressing HEK293 cells. Previous studies have demonstrated that PGC-1α expression leads to expression of antioxidants such as SOD and catalase (10, 26) and provided evidence that PGC-1α can protect neuroblastoma cells from H 2 O 2 -mediated cell death (10) . In this study, to evaluate the role of PGC-1α in providing a defense against oxidative stress, wild-type HEK293 and PGC-1α-overexpressing HEK293 cells were treated with various concentrations of H 2 O 2 for 24 h; the extent of apoptosis was determined using Annexin V-PI staining. Approximately 72.7% of the empty vector-expressing (Fig. 4A) . Consistent with these changes, wild-type HEK293 cells had significantly higher intracellular levels of ROS than PGC-1α-transfected HEK293 cells did (5.64±0.55-vs. 1.91±0.22-and 2.38±0.30-fold, P<0.01 and P<0.05, respectively), as indicated by increased fluorescence in the presence of the compound DCF-DA (Fig. 4B) . In addition, the basal level of ROS was determined in wild-type, PGC-1α-HEK293 #1 and PGC-1α-HEK293 #3 cells. The basal level of ROS was reduced in PGC-1α-transfected cells compared with wild-type HEK293 cells (0.60±0.03-and 0.57±0.01-fold vs. 1, respectively) (Fig. 4B) . The reduced basal ROS of PGC-1α-HEK293 cells may be related to the increased expression of antioxidants. The expression of catalase was significantly 2.62-and 2.52-fold increased in PGC-1α-transfected HEK293 (PGC-1α-HEK293 #1 and #3) cells, respectively (Fig. 4C) . The expression of SOD was significantly 1.85-and 1.62-fold increased in PGC-1α-transfected HEK293 (PGC-1α-HEK293 #1 and #3) cells, respectively (Fig. 4C) . To confirm these results, the extent of H 2 O 2 -induced apoptosis and ROS level were measured in PGC-1α-siRNA-or non-specific control siRNA-transfected PGC-1α-HEK293 #1 and SNU-C4 cells. The extent of H 2 O 2 -induced apoptosis and ROS level were significantly increased in PGC-1α-siRNA-transfected PGC-1α-HEK293 #1 and SNU-C4 cells ( Fig. 4D and E) . The increased basal ROS of PGC-1α-siRNA-transfected PGC-1α-HEK293 #1 and SNU-C4 cells may be caused by the decreased expression of antioxidants. Expression of SOD and catalase was decreased in PGC-1α-siRNA-transfected PGC-1α-HEK293 #1 and SNU-C4 cells (Fig. 6A) . These results indicate that PGC-1α can protect HEK293 cells from oxidative stress such as that caused by H 2 O 2 . Decreased susceptibility to ROS-induced apoptosis may contribute to increased cell proliferation in PGC-1α-HEK293 cells. 
Overexpression of PGC-1α may lead to upregulation of acylCoA binding protein (ACBP) in HEK293 cells.
To investigate genes that contribute to PGC-1α-induced cell proliferation and tumorigenesis, ACP-based GeneFishing PCR was performed, and the band intensities between PGC-1α-transfected HEK293 cells and empty vector-expressing HEK293 cells were compared. By densitometric analysis of amplified cDNA fragments, one fragment showing >2-fold different intensities between two cell lines was observed (Fig. 5A) . The amplicon band was eluted from agarose gel, re-amplified, and sequenced, and the sequences were used in a BLAST search to identify their gene annotations. BLAST analysis identified the ACBP.
To confirm the upregulated expression of ACBP in PGC-1α-overexpressing HEK293 cells, real-time RT-PCR, immunoblot analysis, and immunofluorescence staining were performed. As shown in Fig. 5B and C, mRNA and protein levels of ACBP were approximately 2.4-and 2-fold (mRNA) and 2.09-and 1.99-fold (protein) higher in PGC-1α-HEK293 #1 and #3 cells, respectively, than in wild-type HEK293 cells. In addition, immunofluorescence staining showed that expression levels of ACBP were increased in PGC-1α-overexpressing HEK293 cells and that most of the ACBP was co-localized with PGC-1α (Fig. 5D) . Furthermore, the expression of ACBP was decreased in PGC-1α siRNA-transfected PGC-1α-HEK293 #1 cells based on western blot results (Fig. 6A) . However, the expression of PGC-1α was not affected by ACBP siRNA knockdown (Fig. 6A) . Thus, these data indicate that the expression of ACBP may be regulated by the activity of PGC-1α.
Downregulation of ACBP leads to decreased cell proliferation and increased sensitivity to H 2 O 2 -induced apoptosis.
The above-described findings indicated that ACBP expression was regulated by PGC-1α. To examine the involvement of ACBP in regulating cell proliferation by PGC-1α expression, ACBP was downregulated in an ACBP siRNA knockdown experiment in PGC-1α-transfected HEK293 cells and SNU-C4 cells. In PGC-1α-transfected HEK293 and SNU-C4 cells, the endogenous expression of ACBP was substantially reduced following transfection with siRNA for ACBP (Fig. 6A) ; whereas, the proliferation of ACBP siRNA-transfected PGC-1α-HEK293 #1 and SNU-C4 cells were significantly inhibited compared to control PGC-1α-HEK293 #1 and SNU-C4 cells ( Fig. 6B; 44 and 30% reductions, respectively) . However, protein levels of PGC-1α were not downregulated in ACBP siRNA-transfected PGC-1α-HEK293 #1 and SNU-C4 cells (Fig. 6A) .
In addition, to evaluate the role of ACBP in the regulation of sensitivity to H 2 O 2 -induced apoptosis, the extent of H 2 O 2 -induced apoptosis and ROS level were measured in ACBP siRNA-transfected or non-silencing siRNA-transfected PGC-1α-HEK293 #1 and SNU-C4 cells. The extent of H 2 O 2 -induced apoptosis and ROS level were significantly increased in ACBP siRNA-transfected PGC-1α-HEK293 #1 and SNU-C4 cells compared to control PGC-1α-HEK293 #1 and SNU-C4 cells (Fig. 6C) . Expression of SOD and catalase was decreased by ACBP siRNA knockdown in PGC-1α-HEK293 and SNU-C4 cells (Fig. 6A) . These results indicate that ACBP can protect PGC-1α-HEK293 #1 and SNU-C4 cells from oxidative stress such as that mediated by H 2 O 2 . Increased susceptibility to ROS-induced apoptosis may contribute to decreased cell proliferation by ACBP siRNA knockdown in PGC-1α-HEK293 #1 and SNU-C4 cells. The decreased cell proliferation and increased sensitivity to H 2 O 2 -induced apoptosis by ACBP knockdown is similar to that observed in PGC-1α siRNA-transfected PGC-1α-HEK293 #1 and SNU-C4 cells. Thus, these results suggest that PGC-1α knockdown downregulates cell proliferation and increases H 2 O 2 -induced apoptosis of HEK293 and SNU-C4 cells through downregulation of ACBP.
PGC-1α does not physically interact with ACBP.
The above results suggested that PGC-1α expression influences ACBP expression, but interactions between PGC-1α and ACBP have not previously been described. Thus, we tested the possibility that PGC-1α can interact with ACBP. Using antibodies against FLAG, we found that FLAG antibody did not immunoprecipitate ACBP (Fig. 7A) . Consistent with this outcome, ACBP antibodies did not immunoprecipitate FLAG-PGC-1α (Fig. 7B) . These results indicate that PGC-1α did not directly interact with ACBP.
Increased Sp1 expression may contribute to increased ACBP expression by PGC-1α. The results described above showed that ACBP is a target of PGC-1α; however, the mechanisms for its regulation by PGC-1α are not clear. A previous report suggests that the promoter of ACBP has an Sp1 binding site (27) . Thus, we investigated whether PGC-1α expression can influence the expression of Sp1. The results indicated that the expression of Sp1 was significantly 3-fold increased in PGC-1α-HEK293 #1 and #3 cells compared to wild-type HEK293 cells (Fig. 8A) . In addition, PGC-1α siRNA transfection led to reduced expression of Sp1 in PGC-1α-HEK293 #1 and SNU-C4 cells (Fig. 6A) .
The knockdown of Sp1 in PGC-1α-HEK293 #1 and SNU-C4 was confirmed by western blot analysis. The expression of Sp1 was decreased in PGC-1α-HEK293 #1 and SNU-C4 cells (Fig. 8B) . Knockdown of Sp1 resulted in decreased cell proliferation, decreased expression of ACBP, decreased expression of catalase and SOD, increased ROS production, and increased H 2 O 2 -induced apoptosis in PGC-1α-HEK293 #1 and SNU-C4 cells (Fig. 8B-D) , which is similar to those 
Discussion
In the present study, PGC-1α-overexpressing HEK293 and CT-26 cells were established, and PGC-1α expression was confirmed by western blotting and immunofluorescence staining. Overexpression of PGC-1α increased cell proliferation and greatly enhanced tumorigenesis in a colony-forming assay and a Balb/c immunodeficient mouse model, suggesting that PGC-1α may be involved in the control of cell proliferation and tumorigenesis. In addition, downregulation of PGC-1α led to decreased cell proliferation in HT-29, SNU-C4, and PGC-1α-HEK293 cells. However, the detailed molecular mechanisms for increased cell proliferation and tumorigenesis by PGC-1α overexpression remain to be clarified, and the role of PGC-1α in cancer has been controversial. Several studies support that PGC-1α has antitumor activity because decreased PGC-1α expression is related to cancer progression and poor prognosis in breast cancer (16) (17) (18) . In addition, PGC-1α overexpression induces apoptosis of ovarian cancer cells through the coordinated regulation of Bcl-2 and Bax expression (19) . In contrast, several studies support that PGC-1α has tumorpromoting activity. For example, PGC-1α protects cells from apoptosis in neuroblastoma cells (20) and promotes cell growth in prostate cancer cells (21) . Increased cell proliferation and tumorigenesis by PGC-1α overexpression observed in this study is consistent with the findings that PGC-1α promotes cell growth in prostate cancer cells and tumor growth (21, 28) .
Previous studies have suggested that ROS have dual roles in cancer promotion (29) or cancer suppression (30, 31) in tumorigenesis. ROS generation is a necessary step during apoptosis because ROS scavengers block or delay apoptosis. PGC-1α induces antioxidant enzymes such as SOD and catalase, resulting in reduced ROS levels in H 2 O 2 -treated neuronal cells (10, 20) . In this study, to confirm whether the increased expression of PGC-1α can protect cells from ROS-induced cell death, the levels of ROS and the extent of apoptosis during H 2 O 2 treatment were assessed. We found that H 2 O 2 -induced ROS production and apoptosis were attenuated by PGC-1α expression. In addition, the extent of H 2 O 2 -induced apoptosis and ROS level were increased in PGC-1α siRNA-transfected PGC-1α-HEK293 and SNU-C4 cells. These results are similar to those showing that PGC-1α can protect neuroblastoma cells from H 2 O 2 -mediated cell death (20) . Thus, the current findings suggest that the decreased ROS-induced apoptosis might contribute to enhanced cell proliferation by PGC-1α.
To identify the molecular targets for PGC-1α, DEGs in control and PGC-1α-HEK293 cells were examined using the GeneFishing DEG screening system. ACBP was found to be upregulated in PGC-1α-overexpressing HEK293 cells. Furthermore, upregulated ACBP expression was confirmed by real-time RT-PCR, western blotting and immunofluorescence staining. In addition, PGC-1α siRNA transfection led to downregulation of ACBP expression in PGC-1α-HEK293 and SNU-C4 cells. However, the expression of PGC-1α was not downregulated by ACBP siRNA transfection. These data suggest that ACBP is a target of PGC-1α. This relationship between PGC-1α and ACBP had not been reported previously. To confirm whether PGC-1α enhances cell proliferation and tumorigenesis through upregulation of ACBP, we performed ACBP siRNA knockdown experiments in PGC-1α-HEK293 and SNU-C4 cells. ACBP knockdown resulted in decreased cell proliferation, increased H 2 O 2 -induced ROS production and apoptosis, and reduced expression of catalase and SOD, which is similar to outcomes for PGC-1α siRNA-transfected PGC-1α-HEK293 and SNU-C4 cells. Taken together, these data provide direct evidence that PGC-1α enhances cell proliferation and tumorigenesis through upregulation of ACBP.
ACBP is reported to play a role in a number of important physiological and biochemical functions, such as regulation of glucose-induced insulin secretion from pancreatic β-cells (32, 33) , stimulation of steroidogenesis through peripheral-type benzodiazepine receptor (PBR) (34) (35) (36) , and modulation of cell proliferation (37) . ACBP/DBI, originally described as a cytosolic protein and identified as stimulating the synthesis of pregnenolone in mitochondrial fractions, enhances steroidogenesis via PBRs. ACBP/DBI does so by promoting cholesterol delivery to the inner mitochondrial membrane (38) , which represents the rate-determining step of steroid biosynthesis (39) . Several lines of evidence indicate that this ligand, which binds at PBRs, may be involved in the regulation of cell growth and differentiation (40) . In addition, serum cholesterol levels and ACBP/DBI are significantly increased in patients with hepatocellular carcinoma (41) . ACBP is localized throughout the cytosol and at organelles such as the Golgi apparatus and endoplasmic reticulum (42) and the nucleus and the perinuclear area (43) . This study showed that most of the ACBP was co-localized with PGC-1α. Thus, we also examined whether PGC-1α directly interacts with ACBP by co-immunoprecipitation; however, PGC-1α did not do so. We sought to identify the molecular mechanism for increased expression of ACBP by PGC-1α. Because a previous study suggested that the ACBP promoter has an Sp1 binding site (27) , we focused on the role of Sp1 in the PGC-1α-ACBP axis, which may be involved in the regulation of cell proliferation, using Sp1 siRNA transfection. Increased expression of Sp1 might contribute to increased expression of ACBP by PGC-1α; however, we did not examine the effect of Sp1 on the promoter activity of ACBP in this study. We cannot exclude some role for SREBP-1c, PPARα, or PPARγ in regulating cell proliferation by PGC-1α because we did not examine their expression, which has been reported to be involved in the regulation of ACBP. Further investigations to clarify the detailed mechanisms for Sp1-induced ACBP expression and increased Sp1 expression by PGC-1α are needed.
Several groups have reported that Sp1 is overexpressed in a variety of cancers and is highly correlated with stage and poor prognosis of the cancers (44) (45) (46) . In the present study, we observed an increased expression of Sp1 in PGC-1α-HEK293 #1 and #3 cells. In addition, Sp1 siRNA transfection resulted in decreased cell proliferation, decreased ACBP expression, decreased expression of catalase and SOD, and increased H 2 O 2 -induced apoptosis, which are similar to those of PGC-1α siRNA transfection in PGC-1α-HEK293 and SNU-C4 cells. Our data are consistent with previous reports that inhibiting or knocking down Sp1 to normal cellular levels usually decreases tumor formation, growth, and metastasis (47) (48) (49) . Previous studies also suggest that catalase and SOD gene transcriptional regulation is highly dependent on Sp1 (50, 51) . Even though we did not examine the promoter activity of catalase and SOD by Sp1, our data support that the decreased expression of Sp1 may contribute to reduced expression of catalase and SOD, increased H 2 O 2 -induced ROS production, and apoptosis. Taken together, we suggest hypothetical molecular mechanisms for increased cell proliferation and tumorigenesis by PGC-1α. In brief, the increased cell proliferation and tumorigenesis by PGC-1α expression may be related to the upregulation of ACBP through increased Sp1 expression; the decreased cell proliferation by Sp1 or ACBP knockdown is similar to that achieved by PGC-1α downregulation, and Sp1 or ACBP expression is downregulated in the PGC-1α siRNA knockdown experiment.
In conclusion, the results of this study suggest that PGC-1α overexpression upregulates proliferation of HEK293 cells through upregulation of ACBP by increased Sp1 expression. Moreover, PGC-1α expression correlates with enhanced tumorigenesis. Further studies to clarify the molecular interactions between PGC-1α and Sp1 are needed. The current findings also suggest that PGC-1α may be a good candidate molecular target for cancer therapeutics because PGC-1α expression is related to enhanced cell proliferation and tumorigenesis.
